View More
For the second time in HIV history, the development of new drugs with novel mechanisms of action and no cross-resistance with any previous antiretroviral drug will allow most highly treatment–experienced patients with resistant HIV to regain virologic suppression.
Josep M. Llibre, MD, PhD
Released: October 18, 2021
In this case example, learn the data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience
John D. Baxter, MD
Released: December 29, 2021
Learn the data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.
John D. Baxter, MD
Released: January 24, 2022
Listen as John D. Baxter, MD, shares the latest data and recommendations for the use of proviral HIV DNA genotyping to inform ART choice for patients with significant ART experience.
John D. Baxter, MD
Released: February 1, 2022
In this case example, learn the data and recommendations for initiating ART in a patient with transmitted antiretroviral drug resistance including why many first line ART options can still be considered.
John D. Baxter, MD
Released: January 5, 2022
Listen as John D. Baxter, MD, shares the latest data and recommendations for initiating ART in patients with transmitted antiretroviral drug resistance.
John D. Baxter, MD
Released: January 25, 2022
Learn data and recommendations for initiating ART in a patient with transmitted antiretroviral drug resistance.
John D. Baxter, MD
Released: January 24, 2022
In this on-demand recording of a live webinar, expert faculty review key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.
W. David Hardy, MD
Josep M. Llibre, MD, PhD
Released: December 29, 2021
Learn key considerations when choosing ART for patients with virologic failure and resistance, including how to build an optimized background regimen and the data to support the inclusion of novel therapies into ART regimens.
W. David Hardy, MD
Josep M. Llibre, MD, PhD
Released: November 29, 2021
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.